Knowledge (XXG)

Lymphocyte function-associated antigen 1

Source đź“ť

92:, an intracellular g-protein. Rap1 assists in breaking the constraint between the alpha and beta subunits of LFA-1. This induces an intermediate extended conformation. The conformational change stimulates a recruitment of proteins to form an activation complex. The activation complex further destabilizes the alpha and beta subunits. Chemokines also stimulate an I-like domain on the beta subunit, which causes the MIDAS site on the beta subunit to bind to glutamate on the I domain of the alpha subunit. This binding process causes the beta subunit to pull down the alpha 7 helix of the I domain, exposing and opening up the MIDAS site on the alpha subunit for binding. This causes LFA-1 to undergo a conformational change to the fully extended conformation. The process of activating LFA-1 is known as inside out signaling, which causes LFA-1 to shift from low affinity to high affinity by opening the ligand-binding site. 117:, a subtype of LAD, is caused by a lack of integrins that contain the beta subunit, including LFA-1. LAD1 is characterized by recurring bacterial infection, delayed (>30 days) separation of umbilical cord, ineffective wound healing and pus formation, and granulocytosis. LAD1 is caused by low expression of CD11 and CD18. CD18 is found on chromosome 21 and CD11 is found on chromosome 16. 100:
Early discovery of cellular adhesion molecules involved the use of monoclonal antibodies to inhibit cellular adhesion processes. The antigen that bound to the monoclonal antibodies was identified as an important molecule in cellular recognition processes. These experiments yielded the protein name
112:
is an immunodeficiency caused by the absence of key adhesion surface proteins, including LFA-1. LAD is a genetic defect caused by autosomal recessive genes. The deficiency causes ineffective migration and phagocytosis for impacted leukocytes. Patients with LAD also have poorly functioning
76:. The ICAM binding site is on the alpha subunit. The general binding region of the alpha subunit is the I-domain. Due to the presence of a divalent cation site in the I-domain, the specific binding site is often referred to as the metal-ion dependent adhesion site (MIDAS). 101:“integrin” as a description of the proteins' integral role in cellular adhesion processes and the transmembrane association between the extracellular matrix and the cytoskeleton. LFA-1, a leukocyte integrin, was first discovered by Timothy Springer in mice in the 1980s. 42:
and other leukocytes. LFA-1 plays a key role in emigration, which is the process by which leukocytes leave the bloodstream to enter the tissues. LFA-1 also mediates firm arrest of leukocytes. Additionally, LFA-1 is involved in the process of
67:
LFA-1 is a heterodimeric glycoprotein with non-covalently linked subunits. LFA-1 has two subunits designated as the alpha subunit and beta subunit. The alpha subunit was named aL in 1983. The alpha subunit is designated
55:, ICAM-3, ICAM-4, ICAM-5, and JAM-A. LFA-1/ICAM-1 interactions have recently been shown to stimulate signaling pathways that influence T cell differentiation. LFA-1 belongs to the 617: 586: 1563: 475:"Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen distinct from Lyt-2,3 that participates in T lymphocyte-mediated killing" 610: 84:
In an inactive state, LFA-1 rests in a bent conformation and has a low affinity for ICAM binding. This bent conformation conceals the MIDAS.
1168: 427:
Anderson DC, Springer TA (1987). "Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins".
1135: 355: 268: 228: 164: 603: 665: 114: 47:
mediated killing as well as antibody mediated killing by granulocytes and monocytes. As of 2007, LFA-1 has 6 known ligands:
655: 126: 109: 1083: 1115: 580: 1161: 1525: 1499: 1494: 1489: 1414: 1404: 1345: 845: 638: 630: 1350: 822: 1462: 1446: 1377: 794: 780: 486: 528:"Secondary T cell-T cell synaptic interactions drive the differentiation of protective CD8+ T cells" 1583: 659: 1588: 1154: 409: 88:
stimulate the activation process of LFA-1. The activation process begins with the activation of
557: 514: 444: 401: 361: 351: 315: 274: 264: 234: 224: 170: 160: 595: 1451: 1382: 1312: 1307: 1261: 960: 626: 547: 539: 504: 494: 436: 393: 305: 217: 44: 490: 440: 1546: 1541: 1520: 552: 527: 526:
GĂ©rard A, Khan O, Beemiller P, Oswald E, Hu J, Matloubian M, Krummel MF (April 2013).
509: 474: 1577: 942: 466:
Janeway, Travers, Walport, Shlomchik, Immunobiology 6th ed. (2005) Garland Science:NY
469:
Parham, Peter, The Immune System 3rd ed. (2009) Garland Science: London and New York
413: 913: 909: 905: 901: 694: 576: 986: 919: 879: 869: 131: 479:
Proceedings of the National Academy of Sciences of the United States of America
1092: 1063: 1058: 1053: 976: 897: 39: 365: 310: 294:"Not Just an Adhesion Molecule: LFA-1 Contact Tunes the T Lymphocyte Program" 293: 278: 238: 174: 889: 689: 85: 590: 561: 499: 405: 319: 518: 448: 1177: 1098: 1045: 854: 758: 647: 56: 35: 473:
Davignon D, Martz E, Reynolds T, KĂĽrzinger K, Springer TA (July 1981).
397: 1355: 1241: 1236: 955: 826: 716: 679: 669: 48: 17: 543: 384:
Akbari H, Zadeh MM (January 2001). "Leukocyte adhesion deficiency".
1509: 1504: 1467: 1435: 1409: 1322: 1317: 1302: 1271: 1266: 1256: 1251: 1246: 1231: 1226: 1221: 1216: 1211: 1206: 1201: 1196: 1191: 1130: 1107: 1103: 1031: 1021: 1016: 1011: 1006: 1001: 950: 830: 812: 808: 798: 784: 770: 746: 741: 736: 731: 726: 721: 704: 699: 673: 69: 52: 1513: 1471: 1455: 1439: 1386: 1359: 1297: 1292: 1287: 1125: 1120: 1087: 1026: 996: 991: 981: 931: 927: 923: 874: 816: 802: 788: 774: 709: 684: 89: 73: 1150: 599: 1146: 72:; and the beta subunit, unique to leukocytes, is beta-2 or 261:
Oxford dictionary of biochemistry and molecular biology
1534: 1482: 1423: 1397: 1370: 1338: 1331: 1280: 1184: 1076: 1044: 969: 941: 888: 862: 853: 844: 757: 646: 637: 263:(Rev. ed.). Oxford: Oxford University Press. 216: 219:Adhesion molecules : function and inhibition 159:(1st ed.). Oxford: Oxford University Press. 134:, a drug that blocks LFA-1 from binding to ICAM-1 348:Protein-protein interactions in drug discovery 1162: 611: 8: 1335: 1169: 1155: 1147: 859: 850: 643: 618: 604: 596: 579:at the U.S. National Library of Medicine 551: 508: 498: 309: 28:Lymphocyte function-associated antigen 1 144: 210: 208: 206: 204: 7: 379: 377: 375: 341: 339: 337: 335: 333: 331: 329: 292:Verma NK, Kelleher D (August 2017). 254: 252: 250: 248: 202: 200: 198: 196: 194: 192: 190: 188: 186: 184: 150: 148: 441:10.1146/annurev.me.38.020187.001135 105:Leukocyte Adhesion Deficiency (LAD) 59:superfamily of adhesion molecules. 1564:cell surface receptor deficiencies 25: 1: 127:Leukocyte adhesion deficiency 110:Leukocyte adhesion deficiency 1424:Leukocyte-adhesion receptor: 386:Indian Journal of Pediatrics 1483:Very late antigen receptor: 157:A dictionary of biomedicine 1605: 1084:Lymphocyte homing receptor 1559: 429:Annual Review of Medicine 1116:Carcinoembryonic antigen 970:Unconventional/ungrouped 581:Medical Subject Headings 311:10.4049/jimmunol.1700495 631:cell adhesion molecules 589:Info with links in the 350:. Weinheim: Wiley-VCH. 591:Cell Migration Gateway 500:10.1073/pnas.78.7.4535 1535:Vitronectin receptor: 1398:Fibronectin receptor: 1351:Glycoprotein IIb/IIIa 1339:Cytoadhesin receptor: 823:Glycoprotein IIb/IIIa 298:Journal of Immunology 223:. Basel: Birkhauser. 1526:Integrin alpha6beta1 1500:Integrin alpha3beta1 1495:Integrin alpha2beta1 1490:Integrin alpha1beta1 1463:Integrin alphaXbeta2 1447:Macrophage-1 antigen 1415:Integrin alpha5beta1 1410:Integrin alpha4beta1 1405:Integrin alpha2beta1 1378:Macrophage-1 antigen 1371:Fibrinogen receptor: 1346:Integrin alpha6beta4 795:Macrophage-1 antigen 781:Integrin alphaXbeta2 660:Myelin protein zero 639:Calcium-independent 491:1981PNAS...78.4535D 398:10.1007/bf02728867 346:Dömling A (2013). 259:Cammack R (2006). 155:Lackie JM (2010). 1571: 1570: 1555: 1554: 1144: 1143: 1072: 1071: 1040: 1039: 846:Calcium-dependent 840: 839: 627:Membrane proteins 532:Nature Immunology 16:(Redirected from 1596: 1336: 1171: 1164: 1157: 1148: 860: 851: 644: 620: 613: 606: 597: 565: 555: 522: 512: 502: 453: 452: 424: 418: 417: 381: 370: 369: 343: 324: 323: 313: 304:(4): 1213–1221. 289: 283: 282: 256: 243: 242: 222: 212: 179: 178: 152: 45:cytotoxic T cell 21: 1604: 1603: 1599: 1598: 1597: 1595: 1594: 1593: 1574: 1573: 1572: 1567: 1551: 1530: 1478: 1419: 1393: 1366: 1327: 1276: 1180: 1175: 1145: 1140: 1068: 1036: 965: 937: 884: 836: 753: 633: 624: 573: 568: 544:10.1038/ni.2547 525: 472: 462: 460:Further reading 457: 456: 426: 425: 421: 383: 382: 373: 358: 345: 344: 327: 291: 290: 286: 271: 258: 257: 246: 231: 214: 213: 182: 167: 154: 153: 146: 141: 123: 107: 98: 82: 65: 23: 22: 15: 12: 11: 5: 1602: 1600: 1592: 1591: 1586: 1576: 1575: 1569: 1568: 1560: 1557: 1556: 1553: 1552: 1550: 1549: 1547:Alpha-v beta-5 1544: 1542:Alpha-v beta-3 1538: 1536: 1532: 1531: 1529: 1528: 1523: 1521:Alpha-5 beta-1 1518: 1517: 1516: 1502: 1497: 1492: 1486: 1484: 1480: 1479: 1477: 1476: 1475: 1474: 1460: 1459: 1458: 1444: 1443: 1442: 1427: 1425: 1421: 1420: 1418: 1417: 1412: 1407: 1401: 1399: 1395: 1394: 1392: 1391: 1390: 1389: 1374: 1372: 1368: 1367: 1365: 1364: 1363: 1362: 1348: 1342: 1340: 1333: 1329: 1328: 1326: 1325: 1320: 1315: 1310: 1305: 1300: 1295: 1290: 1284: 1282: 1278: 1277: 1275: 1274: 1269: 1264: 1259: 1254: 1249: 1244: 1239: 1234: 1229: 1224: 1219: 1214: 1209: 1204: 1199: 1194: 1188: 1186: 1182: 1181: 1176: 1174: 1173: 1166: 1159: 1151: 1142: 1141: 1139: 1138: 1133: 1128: 1123: 1118: 1112: 1111: 1095: 1090: 1080: 1078: 1074: 1073: 1070: 1069: 1067: 1066: 1061: 1056: 1050: 1048: 1042: 1041: 1038: 1037: 1035: 1034: 1029: 1024: 1019: 1014: 1009: 1004: 999: 994: 989: 984: 979: 973: 971: 967: 966: 964: 963: 958: 953: 947: 945: 939: 938: 936: 935: 917: 894: 892: 886: 885: 883: 882: 877: 872: 866: 864: 857: 848: 842: 841: 838: 837: 835: 834: 820: 806: 792: 778: 763: 761: 755: 754: 752: 751: 750: 749: 744: 739: 734: 729: 724: 714: 713: 712: 707: 702: 697: 687: 682: 677: 663: 652: 650: 641: 635: 634: 625: 623: 622: 615: 608: 600: 594: 593: 584: 572: 571:External links 569: 567: 566: 523: 470: 467: 463: 461: 458: 455: 454: 419: 371: 356: 325: 284: 269: 244: 229: 215:Ley K (2007). 180: 165: 143: 142: 140: 137: 136: 135: 129: 122: 119: 106: 103: 97: 94: 81: 78: 64: 61: 24: 14: 13: 10: 9: 6: 4: 3: 2: 1601: 1590: 1587: 1585: 1582: 1581: 1579: 1566: 1565: 1558: 1548: 1545: 1543: 1540: 1539: 1537: 1533: 1527: 1524: 1522: 1519: 1515: 1511: 1508: 1507: 1506: 1503: 1501: 1498: 1496: 1493: 1491: 1488: 1487: 1485: 1481: 1473: 1469: 1466: 1465: 1464: 1461: 1457: 1453: 1450: 1449: 1448: 1445: 1441: 1437: 1434: 1433: 1432: 1429: 1428: 1426: 1422: 1416: 1413: 1411: 1408: 1406: 1403: 1402: 1400: 1396: 1388: 1384: 1381: 1380: 1379: 1376: 1375: 1373: 1369: 1361: 1357: 1354: 1353: 1352: 1349: 1347: 1344: 1343: 1341: 1337: 1334: 1330: 1324: 1321: 1319: 1316: 1314: 1311: 1309: 1306: 1304: 1301: 1299: 1296: 1294: 1291: 1289: 1286: 1285: 1283: 1279: 1273: 1270: 1268: 1265: 1263: 1260: 1258: 1255: 1253: 1250: 1248: 1245: 1243: 1240: 1238: 1235: 1233: 1230: 1228: 1225: 1223: 1220: 1218: 1215: 1213: 1210: 1208: 1205: 1203: 1200: 1198: 1195: 1193: 1190: 1189: 1187: 1183: 1179: 1172: 1167: 1165: 1160: 1158: 1153: 1152: 1149: 1137: 1134: 1132: 1129: 1127: 1124: 1122: 1119: 1117: 1114: 1113: 1109: 1105: 1101: 1100: 1096: 1094: 1091: 1089: 1085: 1082: 1081: 1079: 1075: 1065: 1062: 1060: 1057: 1055: 1052: 1051: 1049: 1047: 1043: 1033: 1030: 1028: 1025: 1023: 1020: 1018: 1015: 1013: 1010: 1008: 1005: 1003: 1000: 998: 995: 993: 990: 988: 985: 983: 980: 978: 975: 974: 972: 968: 962: 959: 957: 954: 952: 949: 948: 946: 944: 943:Protocadherin 940: 933: 929: 925: 921: 918: 915: 911: 907: 903: 899: 896: 895: 893: 891: 887: 881: 878: 876: 873: 871: 868: 867: 865: 861: 858: 856: 852: 849: 847: 843: 832: 828: 824: 821: 818: 814: 810: 807: 804: 800: 796: 793: 790: 786: 782: 779: 776: 772: 768: 765: 764: 762: 760: 756: 748: 745: 743: 740: 738: 735: 733: 730: 728: 725: 723: 720: 719: 718: 715: 711: 708: 706: 703: 701: 698: 696: 693: 692: 691: 688: 686: 683: 681: 678: 675: 671: 667: 664: 661: 657: 654: 653: 651: 649: 645: 642: 640: 636: 632: 628: 621: 616: 614: 609: 607: 602: 601: 598: 592: 588: 585: 582: 578: 575: 574: 570: 563: 559: 554: 549: 545: 541: 538:(4): 356–63. 537: 533: 529: 524: 520: 516: 511: 506: 501: 496: 492: 488: 485:(7): 4535–9. 484: 480: 476: 471: 468: 465: 464: 459: 450: 446: 442: 438: 434: 430: 423: 420: 415: 411: 407: 403: 399: 395: 391: 387: 380: 378: 376: 372: 367: 363: 359: 357:9783527648238 353: 349: 342: 340: 338: 336: 334: 332: 330: 326: 321: 317: 312: 307: 303: 299: 295: 288: 285: 280: 276: 272: 270:9780191727641 266: 262: 255: 253: 251: 249: 245: 240: 236: 232: 230:9783764379759 226: 221: 220: 211: 209: 207: 205: 203: 201: 199: 197: 195: 193: 191: 189: 187: 185: 181: 176: 172: 168: 166:9780191727948 162: 158: 151: 149: 145: 138: 133: 130: 128: 125: 124: 120: 118: 116: 113:neutrophils. 111: 104: 102: 95: 93: 91: 87: 79: 77: 75: 71: 62: 60: 58: 54: 50: 46: 41: 37: 33: 29: 19: 1561: 1430: 1097: 766: 535: 531: 482: 478: 432: 428: 422: 389: 385: 347: 301: 297: 287: 260: 218: 156: 108: 99: 83: 66: 31: 27: 26: 920:Desmocollin 587:ITGAL ITGB2 392:(1): 77–9. 132:Lifitegrast 40:lymphocytes 1584:Immunology 1578:Categories 1093:L-selectin 1064:P-selectin 1059:L-selectin 1054:E-selectin 977:T-cadherin 898:Desmoglein 890:Desmosomal 435:: 175–94. 139:References 86:Chemokines 80:Activation 1589:Integrins 1562:see also 1178:Integrins 1046:Selectins 863:Classical 855:Cadherins 759:Integrins 690:L1 family 366:828743731 279:743217704 239:261225084 175:663104793 96:Discovery 63:Structure 38:found on 1099:integrin 648:IgSF CAM 562:23475183 414:11336052 406:11237241 320:28784685 121:See also 57:integrin 36:integrin 34:) is an 553:3962671 519:7027264 487:Bibcode 449:3555290 1356:ITGA2B 1332:Dimers 961:PCDH19 956:PCDH15 827:ITGA2B 717:Nectin 695:L1-CAM 685:PE-CAM 680:VCAM-1 583:(MeSH) 560:  550:  517:  510:319826 507:  447:  412:  404:  364:  354:  318:  277:  267:  237:  227:  173:  163:  53:ICAM-2 49:ICAM-1 1510:CD49d 1505:VLA-4 1468:CD11c 1452:CD11b 1436:CD11a 1431:LFA-1 1383:CD11b 1360:ITGB3 1185:Alpha 1136:EpCAM 1131:CD146 1108:LFA-1 1104:VLA-4 1077:Other 1032:CDH10 1022:CDH17 1017:CDH16 1012:CDH15 1007:CDH12 1002:CDH11 951:PCDH1 831:ITGB3 813:CD49d 809:VLA-4 799:CD11b 785:CD11c 771:CD11a 767:LFA-1 747:CD155 742:CADM3 737:CADM1 732:PVRL3 727:PVRL2 722:PVRL1 705:NFASC 700:NRCAM 656:N-CAM 577:LFA-1 410:S2CID 70:CD11a 32:LFA-1 18:LFA-1 1514:CD29 1472:CD18 1456:CD18 1440:CD18 1387:CD18 1281:Beta 1126:CD44 1121:CD24 1088:CD44 1027:CDH9 997:CDH8 992:CDH6 987:CDH5 982:CDH4 932:DSC3 928:DSC2 924:DSC1 914:DSG4 910:DSG3 906:DSG2 902:DSG1 880:CDH3 875:CDH2 870:CDH1 817:CD29 803:CD18 789:CD18 775:CD18 710:CHL1 666:ICAM 558:PMID 515:PMID 445:PMID 402:PMID 362:OCLC 352:ISBN 316:PMID 275:OCLC 265:ISBN 235:OCLC 225:ISBN 171:OCLC 161:ISBN 115:LAD1 90:Rap1 74:CD18 1242:A11 1237:A10 548:PMC 540:doi 505:PMC 495:doi 437:doi 394:doi 306:doi 302:199 1580:: 1323:B8 1318:B7 1313:B6 1308:B5 1303:B4 1298:B3 1293:B2 1288:B1 1272:AX 1267:AV 1262:AM 1257:AL 1252:AE 1247:AD 1232:A9 1227:A8 1222:A7 1217:A6 1212:A5 1207:A4 1202:A3 1197:A2 1192:A1 1106:, 1086:: 930:, 926:, 912:, 908:, 904:, 672:, 629:: 556:. 546:. 536:14 534:. 530:. 513:. 503:. 493:. 483:78 481:. 477:. 443:. 433:38 431:. 408:. 400:. 390:68 388:. 374:^ 360:. 328:^ 314:. 300:. 296:. 273:. 247:^ 233:. 183:^ 169:. 147:^ 51:, 1512:+ 1470:+ 1454:+ 1438:+ 1385:+ 1358:+ 1170:e 1163:t 1156:v 1110:) 1102:( 934:) 922:( 916:) 900:( 833:) 829:+ 825:( 819:) 815:+ 811:( 805:) 801:+ 797:( 791:) 787:+ 783:( 777:) 773:+ 769:( 676:) 674:5 670:1 668:( 662:) 658:( 619:e 612:t 605:v 564:. 542:: 521:. 497:: 489:: 451:. 439:: 416:. 396:: 368:. 322:. 308:: 281:. 241:. 177:. 30:( 20:)

Index

LFA-1
integrin
lymphocytes
cytotoxic T cell
ICAM-1
ICAM-2
integrin
CD11a
CD18
Chemokines
Rap1
Leukocyte adhesion deficiency
LAD1
Leukocyte adhesion deficiency
Lifitegrast


ISBN
9780191727948
OCLC
663104793








Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

↑